Immunostimulant mRNA vaccine TriMix, encoding CD70, CD40L, and a constitutively active form of TLR4 produced vigorous CD8+ T cell responses in patients with stage III or IV melanoma, showing favorable tumor response rates in phase II clinical trial (43). This evidence concerns the gene CD8A and neoplasm.